TY - JOUR
T1 - Antineoplastic effect of 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in transgenic mice with retinoblastoma
AU - Shternfeld, Ilona Slusker
AU - Lasudry, Jacques G.H.
AU - Chappell, Richard J.
AU - Darjatmoko, Soesiawati R.
AU - Albert, Daniel M.
PY - 1996/11
Y1 - 1996/11
N2 - Objective: To evaluate the in vivo efficacy and clinical toxic effects of the 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in β-luteinizing hormone-Tag (LHβ-Tag) transgenic mice with heritable retinoblastoma. Methods: Forty-two mice (8-10 weeks old), randomly assigned to experimental (n=21) or control (n=21) groups, received intraperitoneal injections of 0.05 μg of 1,25-dihydroxy-16-ene-23-yne-D3 in 0.5-mL mineral oil vehicle (experimental group) or 0.5 mL of mineral oil vehicle (control group) for 5 weeks. One experimental and 3 control animals died of injection-related trauma. Eyes were enucleated 1 week after treatment and were examined histologically in a masked fashion. Results: All experimental and control animals showed evidence of tumor. The tumors in the experimental mice showed a significantly smaller cross-sectional area (0.88±0.08 mm2) compared with that in the control mice (1.12±0.12 mm2) (P=.02). All mice completed the treatment and showed no clinical evidence of toxic effects. Conclusions: Tumors in transgenic mice with retinoblastoma treated with 1,25(OH)2-16- ene-23-yne-D3 showed a 21% smaller cross sectional area compared with that in the control mice, without producing clinically apparent toxic effects. This compound may be useful as adjunctive therapy in the treatment of retinoblastoma.
AB - Objective: To evaluate the in vivo efficacy and clinical toxic effects of the 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in β-luteinizing hormone-Tag (LHβ-Tag) transgenic mice with heritable retinoblastoma. Methods: Forty-two mice (8-10 weeks old), randomly assigned to experimental (n=21) or control (n=21) groups, received intraperitoneal injections of 0.05 μg of 1,25-dihydroxy-16-ene-23-yne-D3 in 0.5-mL mineral oil vehicle (experimental group) or 0.5 mL of mineral oil vehicle (control group) for 5 weeks. One experimental and 3 control animals died of injection-related trauma. Eyes were enucleated 1 week after treatment and were examined histologically in a masked fashion. Results: All experimental and control animals showed evidence of tumor. The tumors in the experimental mice showed a significantly smaller cross-sectional area (0.88±0.08 mm2) compared with that in the control mice (1.12±0.12 mm2) (P=.02). All mice completed the treatment and showed no clinical evidence of toxic effects. Conclusions: Tumors in transgenic mice with retinoblastoma treated with 1,25(OH)2-16- ene-23-yne-D3 showed a 21% smaller cross sectional area compared with that in the control mice, without producing clinically apparent toxic effects. This compound may be useful as adjunctive therapy in the treatment of retinoblastoma.
UR - http://www.scopus.com/inward/record.url?scp=0029966737&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029966737&partnerID=8YFLogxK
U2 - 10.1001/archopht.1996.01100140596012
DO - 10.1001/archopht.1996.01100140596012
M3 - Article
C2 - 8906031
AN - SCOPUS:0029966737
SN - 0003-9950
VL - 114
SP - 1396
EP - 1401
JO - Archives of ophthalmology
JF - Archives of ophthalmology
IS - 11
ER -